JP2023545372A5 - - Google Patents

Info

Publication number
JP2023545372A5
JP2023545372A5 JP2023518752A JP2023518752A JP2023545372A5 JP 2023545372 A5 JP2023545372 A5 JP 2023545372A5 JP 2023518752 A JP2023518752 A JP 2023518752A JP 2023518752 A JP2023518752 A JP 2023518752A JP 2023545372 A5 JP2023545372 A5 JP 2023545372A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
hypomania
mania
dexmedetomidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545372A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/054171 external-priority patent/WO2022076818A1/en
Publication of JP2023545372A publication Critical patent/JP2023545372A/ja
Publication of JP2023545372A5 publication Critical patent/JP2023545372A5/ja
Pending legal-status Critical Current

Links

JP2023518752A 2020-10-08 2021-10-08 デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療 Pending JP2023545372A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089135P 2020-10-08 2020-10-08
US63/089,135 2020-10-08
PCT/US2021/054171 WO2022076818A1 (en) 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride

Publications (2)

Publication Number Publication Date
JP2023545372A JP2023545372A (ja) 2023-10-30
JP2023545372A5 true JP2023545372A5 (cg-RX-API-DMAC7.html) 2024-10-15

Family

ID=81126063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518752A Pending JP2023545372A (ja) 2020-10-08 2021-10-08 デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療

Country Status (11)

Country Link
US (1) US20240024289A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225305A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023545372A (cg-RX-API-DMAC7.html)
KR (1) KR20230084186A (cg-RX-API-DMAC7.html)
CN (1) CN116615243A (cg-RX-API-DMAC7.html)
AU (1) AU2021356687A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195133A1 (cg-RX-API-DMAC7.html)
IL (1) IL301971A (cg-RX-API-DMAC7.html)
MX (1) MX2023003993A (cg-RX-API-DMAC7.html)
TW (1) TW202228682A (cg-RX-API-DMAC7.html)
WO (1) WO2022076818A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
IL279713B2 (en) 2018-06-27 2025-01-01 Bioxcel Therapeutics Inc Dexmedetomidine-containing layer compositions and methods for their production
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN
EP4297871A4 (en) * 2021-02-26 2025-01-01 BioXcel Therapeutics, Inc. METHODS AND COMPOSITIONS FOR TREATING AGITATION
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
MX368880B (es) * 2012-10-15 2019-10-21 Orion Corp Dexmedetomidina y medetomidina para su uso en el alivio de la aversión al ruido en un animal.
TWI624278B (zh) * 2013-10-07 2018-05-21 帝國製藥美國股份有限公司 使用非鎮靜性右美托咪啶經皮組成物用於治療戒斷症候群的方法及組成物
IL267689B2 (en) * 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
EP3999058A4 (en) * 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN

Similar Documents

Publication Publication Date Title
JP2025092508A5 (cg-RX-API-DMAC7.html)
JP2023041862A5 (cg-RX-API-DMAC7.html)
JP2024109585A5 (cg-RX-API-DMAC7.html)
JP2022191257A5 (cg-RX-API-DMAC7.html)
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2024540183A5 (cg-RX-API-DMAC7.html)
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
JP2025020117A5 (cg-RX-API-DMAC7.html)
JP2022163049A5 (cg-RX-API-DMAC7.html)
JP2021152008A5 (cg-RX-API-DMAC7.html)
JP2023175694A5 (cg-RX-API-DMAC7.html)
FI3746126T3 (fi) Menetelmiä ja koostumuksia uniapnean tai pelkän kuorsauksen hoitamiseksi
JP2005507892A5 (cg-RX-API-DMAC7.html)
JP2002528502A5 (cg-RX-API-DMAC7.html)
JP2005508963A5 (cg-RX-API-DMAC7.html)
JP2021073257A5 (cg-RX-API-DMAC7.html)
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2025508004A5 (cg-RX-API-DMAC7.html)
JP2023531675A5 (cg-RX-API-DMAC7.html)
JP2007509146A5 (cg-RX-API-DMAC7.html)
JP2019514990A5 (cg-RX-API-DMAC7.html)
JP2022551691A5 (cg-RX-API-DMAC7.html)
JP2024514112A5 (cg-RX-API-DMAC7.html)
JP2023553253A5 (cg-RX-API-DMAC7.html)